Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)

In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with Sunitinib.

Inclusion Criteria:

• 18 to 75 years
• Understanding of written German
• Treatment with Sunitinib
• Ability to walk

Exclusion Criteria:

• Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise
• BMI < 18 or > 30